Blockchain Registration Transaction Record

NanoViricides Advances Oral Gummies for Ebola Toward Phase II Trial in DRC

NanoViricides advances oral gummies formulation NV-387 for Ebola toward Phase II trial in DRC, offering potential advantages in outbreak settings with no approved treatments for Bundibugyo strain.

This news matters because it highlights a potential breakthrough in treating the Bundibugyo ebolavirus outbreak in the DRC, where no approved treatments or vaccines exist. The oral gummies formulation of NV-387 could revolutionize outbreak response by enabling easier administration in resource-limited settings compared to intravenous therapies. Success could also pave the way for broad-spectrum antiviral treatments against multiple viral threats, including Mpox and COVID-19, offering hope for global health security.